MX367165B - Formulaciones farmacéuticas para administración subcutánea de furosemida. - Google Patents

Formulaciones farmacéuticas para administración subcutánea de furosemida.

Info

Publication number
MX367165B
MX367165B MX2015014064A MX2015014064A MX367165B MX 367165 B MX367165 B MX 367165B MX 2015014064 A MX2015014064 A MX 2015014064A MX 2015014064 A MX2015014064 A MX 2015014064A MX 367165 B MX367165 B MX 367165B
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
furosemide
subcutaneous administration
aminomethane
hydroxymethyl
Prior art date
Application number
MX2015014064A
Other languages
English (en)
Other versions
MX2015014064A (es
Inventor
A Michaels Scott
Muntendam Pieter
R Larsen Glenn
Original Assignee
Scpharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scpharmaceuticals Inc filed Critical Scpharmaceuticals Inc
Publication of MX2015014064A publication Critical patent/MX2015014064A/es
Publication of MX367165B publication Critical patent/MX367165B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invención se refiere a formulaciones farmacéuticas de furosemida, en donde las formulaciones farmacéuticas incluyen un exceso mola de tris(hidroximetil)aminometano a furosemida, tienen un pH en la escala de 7 a 8.5, y una concentración de tris(hidroximetil)aminometano mayor que o igual a aproximadamente 50 mM. La presente invención puede mejorar la estabilidad de las formulaciones farmacéuticas líquidas incluyendo furosemida y la estabilidad de dichas formulaciones farmacéuticas para administración o suministro subcutáneo.
MX2015014064A 2013-04-05 2014-04-03 Formulaciones farmacéuticas para administración subcutánea de furosemida. MX367165B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361808962P 2013-04-05 2013-04-05
PCT/US2014/032800 WO2014165660A1 (en) 2013-04-05 2014-04-03 Pharmaceutical formulations for subcutaneous administration of furosemide

Publications (2)

Publication Number Publication Date
MX2015014064A MX2015014064A (es) 2017-04-13
MX367165B true MX367165B (es) 2019-08-07

Family

ID=51659206

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014064A MX367165B (es) 2013-04-05 2014-04-03 Formulaciones farmacéuticas para administración subcutánea de furosemida.

Country Status (15)

Country Link
US (4) US9884039B2 (es)
EP (2) EP3799869A1 (es)
JP (2) JP6415535B2 (es)
KR (2) KR102266460B1 (es)
CN (1) CN105431145B (es)
AU (1) AU2014248164B2 (es)
CA (1) CA2908935C (es)
DK (1) DK2981258T3 (es)
ES (1) ES2823589T3 (es)
HK (1) HK1221152A1 (es)
IL (1) IL241917B (es)
MX (1) MX367165B (es)
PT (1) PT2981258T (es)
SG (2) SG11201508251RA (es)
WO (1) WO2014165660A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102266460B1 (ko) 2013-04-05 2021-06-17 에스씨파마슈티칼스 인코포레이티드 퓨로세마이드의 피하 투여용 약학 제형
DE102014115951A1 (de) 2014-11-03 2016-05-04 Merlion Pharmaceuticals Pte Ltd. Zusammensetzungen, die Finafloxacin und Tris enthalten
EP3893843A1 (en) * 2018-12-10 2021-10-20 SQ Innovation AG Pharmaceutical compositions of furosemide and uses thereof
US11246851B2 (en) 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
JP7465881B2 (ja) 2019-01-31 2024-04-11 エスシーファーマシューティカルズ インコーポレイテッド フロセミドの濃縮液体医薬製剤及びそれを投与する方法
CA3190585A1 (en) * 2020-08-05 2022-02-10 Scpharmaceuticals Inc. Methods of treatment using furosemide
EP4313026A1 (en) 2021-04-02 2024-02-07 scPharmaceuticals Inc. Subcutaneous infusion of furosemide

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663348A (en) * 1985-07-02 1987-05-05 Warner-Lambert Co. Furosemide salts and pharmaceutical preparations thereof
US4698361A (en) * 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
DE3623620A1 (de) * 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
WO1992021769A1 (en) * 1991-05-30 1992-12-10 Abbott Laboratories Reagents containing a nonspecific binding blocker in ion-capture binding assays
US5633240A (en) * 1994-09-01 1997-05-27 Academic Pharmaceuticals Parenteral solutions containing metolazone
IT1283608B1 (it) * 1996-04-17 1998-04-22 Ricerche Di Schiena Snc Di Dr Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva.
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
PL1803934T3 (pl) 2005-12-28 2009-03-31 Sensile Pat Ag Mikropompa
MX2009000385A (es) 2006-07-12 2009-04-06 Univ Tennessee Res Foundation Acil-anilidas sustituidas y metodos de uso de las mismas.
EP2022518A1 (en) 2007-08-07 2009-02-11 Sensile Pat AG Modular drug delivery device for administering discrete doses of a medicament
US7923447B2 (en) * 2008-03-17 2011-04-12 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone
AU2009246114B2 (en) * 2008-05-16 2013-01-31 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
MX340669B (es) * 2008-09-09 2016-07-20 Cima Labs Inc Formas farmaceuticas para compuestos debilmente ionizables.
MX2012002762A (es) * 2009-09-04 2012-06-12 Minipumps Llc Parche cutaneo adhesivo con bomba para suministro subcutaneo de farmacos.
WO2013059735A1 (en) 2011-10-19 2013-04-25 Mercator Medsystems, Inc. Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation
KR102266460B1 (ko) 2013-04-05 2021-06-17 에스씨파마슈티칼스 인코포레이티드 퓨로세마이드의 피하 투여용 약학 제형

Also Published As

Publication number Publication date
KR20160014592A (ko) 2016-02-11
EP2981258B1 (en) 2020-08-12
JP2016515623A (ja) 2016-05-30
WO2014165660A1 (en) 2014-10-09
AU2014248164A1 (en) 2015-10-15
CN105431145B (zh) 2019-12-10
US10272064B2 (en) 2019-04-30
US20180303790A1 (en) 2018-10-25
EP2981258A4 (en) 2016-10-05
CA2908935C (en) 2021-06-15
JP2019001821A (ja) 2019-01-10
KR102493735B1 (ko) 2023-01-30
DK2981258T3 (da) 2020-10-19
US20160051507A1 (en) 2016-02-25
EP2981258B8 (en) 2020-11-11
EP3799869A1 (en) 2021-04-07
US20230201156A1 (en) 2023-06-29
SG11201508251RA (en) 2015-11-27
PT2981258T (pt) 2020-10-19
JP6677779B2 (ja) 2020-04-08
KR20210075211A (ko) 2021-06-22
EP2981258A1 (en) 2016-02-10
JP6415535B2 (ja) 2018-10-31
KR102266460B1 (ko) 2021-06-17
US11433044B2 (en) 2022-09-06
CA2908935A1 (en) 2014-10-09
BR112015025204A2 (pt) 2021-03-16
ES2823589T3 (es) 2021-05-07
US20200038364A1 (en) 2020-02-06
HK1221152A1 (zh) 2017-05-26
MX2015014064A (es) 2017-04-13
CN105431145A (zh) 2016-03-23
AU2014248164B2 (en) 2019-05-23
IL241917B (en) 2020-10-29
SG10201709388QA (en) 2017-12-28
US9884039B2 (en) 2018-02-06

Similar Documents

Publication Publication Date Title
MX2015014064A (es) Formulaciones farmaceuticas para administracion subcutanea de furosemida.
SG10201806539XA (en) Liquid protein formulations containing ionic liquids
AU2011208075B2 (en) Stabilized antibody-containing liquid formulations
NZ711567A (en) Antibody formulations
EP4309643A3 (en) Viscosity-reducing excipient compounds for protein formulations
EA033399B1 (ru) Аналоги глюкагона с повышенной растворимостью и/или стабильностью и их применение
MX2016005395A (es) Formulacion estable de insulina glulisina.
MX2014004725A (es) Formulaciones de etanercept estabilizadas con aminoacidos.
EA201890417A1 (ru) Генетически кодируемые, внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения
BR112015000203A2 (pt) formulações de etanercept que exibem redução marcada em partículas sub-visíveis
MX352823B (es) Formulaciones de proteinas que contienen aminoacidos.
MX2015010191A (es) Metodos para tratar infecciones microbianas, incluyendo mastitis.
CL2015003738A1 (es) Formulación líquida estable de amg-416 (velcalcetida)
TR201909447T4 (tr) Aramkol tuzları.
TN2014000498A1 (en) Pharmaceutical formulation
IN2014DN08870A (es)
MX2014009660A (es) Formulacion de anticuerpo anti-selectina p.
PH12019502645A1 (en) Non-reversible humidity indicator card
MX2016009458A (es) Solucion alcoholica estable de alprostadilo.
MD20170071A2 (ro) Compoziţii injectabile de paracetamol
MX2016008170A (es) Proteinas de fusion que comprenden factor ix para tratamiento profilactico de hemofilia y metodos para este.
UA107945U (uk) Готовий лікарський засіб гіпоамоніємічної дії
UA95820U (uk) Комплексний препарат "ремівітал"
UA85573U (ru) Способ нивелирования стресс-индуцированной гипергликемии при острых критических состояниях
MY177091A (en) Sterically stabilized palmitoleic acid liposome

Legal Events

Date Code Title Description
FG Grant or registration